$heff's $tation of $tocks & $olid DD

[pmony5]

TTNP nice reminder Sheff also Analyst Jason Napodano thoughts on clinical data of TTNP

http://bionapcfa.blogspot.com/search/label/Titan%20Pharma

Titan completed two phase III trials and two long-term safety analyses with Probuphine. Data from the first phase III trial was published in JAMA (2010; 304(14):1576-1583) in October 2010. Various posters of the data have been presented at the American College of Neuropsychopharmacology in December 2009 (ACNP Poster-1), the International Society of Addiction Medicine in September 2011 (ISAM Poster-2), and the American Society of Addiction Medicine in April 2012 (ASAM Poster-3).

We view the data as impressive. Probuphine works, and the concept is ideally suited for curbing addictive behavior without risk of accidental exposure or misuse / abuse. We're bullish on the prospects for the drug. We base our opinion on the strong clinical data, the thoughtful and rational design for the product, and various conversations we've had with management and lead investigators from the confirmatory phase III trial. In August 2011, Titan hosted a call with Dr. Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and Dr. Richard N. Rosenthal, M.D., Chairman of Psychiatry at St. Luke's-Roosevelt Hospital Center, a teaching hospital of Columbia University, past president of the American Academy of Addiction Psychiatry. Both doctors expressed their enthusiasm for Probuphine and why they believe it will see meaningful commercial uptake.

As noted above, in the U.S. there are an estimated 3.7 million individuals addicted to opioids. Currently, Suboxone does around 500,000 prescriptions monthly. We model that Probuphine can capture 20% of these patients at a cost of around $2,000 per course of treatment, with an estimated 40% of patients requiring two implants. Therefore, in the U.S. alone, Probuphine is a $280 million product.